Panahi and Nasirian tested rosemary against minoxidil, with limits clear

Two reference trials compared rosemary oil with minoxidil 2%, and later studies examined peptides, low dose oral minoxidil and regenerative care. The evidence picture came into focus with the June 2026 guide and a 90 day trial reported before 10 September 2026.

Panahi and colleagues assigned 100 people with androgenetic alopecia to rosemary oil or minoxidil 2% for six months in 2015. Hair counts rose significantly from baseline in each group, with no significant difference between the groups. Itching of the scalp occurred more often with minoxidil, at 44.4% compared with 15% for rosemary, and dandruff occurred more often with minoxidil, at 32.2% compared with 7.5% for rosemary.

Nasirian and colleagues assigned 60 participants to 2% rosemary oil or 2% minoxidil for 24 weeks in 2020. Hair count increased 10% with rosemary and 13% with minoxidil, with p equals 0.12. The similarity deserves attention, and the dose deserves equal attention. Both trials tested 2% minoxidil, not the stronger 5% formulation many adults use, so similarity does not establish equivalence to present standard dosing.

The most recent rosemary evidence combines the plant with lavender against a control. Patel and colleagues assigned 90 participants in 2025 to rosemary-lavender oil, a peptide formulation or control for 90 days. The rosemary-lavender group increased hair growth rate by 57.73% versus control at p less than 0.0001. The same group increased thickness by 68.70% and density by about 32% versus control, while shedding declined by more than 40%.

Laboratory work suggests one possible mechanism. In 2013 Murata and colleagues reported that rosemary leaf extract blocked 5 alpha reductase by 82.4 percent at 200 ug per mL and 94.6 percent at 500 ug per mL in lab dishes. In that same lab test finasteride produced 81.9 percent inhibition. Results in glassware do not tell us what will happen on a scalp.

Peptides remain earlier in the evidence base. A phase 2A trial of PP405, a peptide meant to activate hair follicle stem cells, found statistically significant regrowth at eight weeks in 78 patients. A telogen effluvium study enrolled 45 subjects aged 18 to 45 in three groups of 15 for 90 days, testing Capilia longa blends, cytokine and peptide blends, and redensyl with aminexil at 2 mL once daily. The samples are small, the follow up is short and the formulas differ.

Low dose oral minoxidil is shifting from clinic habit toward shared standards. An international consensus on starting and monitoring it took 4th place as a poster at the 2024 American Academy of Dermatology Annual Meeting. It listed daily ranges of 0.625 to 2.5 mg for adolescent females, 0.625 to 5 mg for adult females, and 1.25 to 5 mg for adolescent and adult males. Benefit is generally seen between 3 to 6 months. That advice rests on expert agreement because larger trials remain limited. A meta analysis found platelet rich plasma raised hair count and density more than controls. “Treatments like PRP are now a common option for early hair loss because they use the body’s own healing signals,” said Dr. Lindsay Bordone, MD, FAAD, dermatologist at Columbia University and the American Academy of Dermatology.

For a slow routine, the tradeoff is clear. Rosemary asks for daily use and patience, with less itch in these trials but no proof of lasting benefit after stopping. It remains unclear whether store oils match standardized preparations or match minoxidil 5 percent over 12 months.

Look for larger trials that test standard 5 percent dosing, stated peptide doses and longer follow up.